期刊文献+

C-erbB-2在子宫颈癌中的表达及临床意义 被引量:1

Expression and the clinical significance of C-erbB-2 in the cervix cancer
原文传递
导出
摘要 目的研究子宫颈癌中C-erbB-2基因的表达,探讨C-erbB-2在宫颈癌发生发展中的作用,及作为一种肿瘤标记物用于临床筛查判断和判断预后的临床意义。方法应用免疫组织化学的方法检测C-erbB-2基因在宫颈癌32例,慢性宫颈炎20例(对照组)的表达。用卡方检验(Chi-Square Test)检测C-erbB-2在实验组和对照组中的表达是否有差异。结果C-erbB-2在慢性宫颈炎、宫颈癌组织中的阳性表达率分别为68.75%、30%,两者间具有统计学意义(P<0.05),C-erbB-2的表达与宫颈癌的临床分期呈正相关(P0.01)。结论C-erbB-2作为影响细胞凋亡因子,在宫颈癌的发生、发展过程中起一定作用。 Objective: Study the expressions of C -erbB -2 gene in cervix cancer, probe into them and play a developing role at the cervical carcinoma, and is used in sifting and checking the clinical meaning that judges and judging the prognosis clinically as a kind of tumour mark thing. Methods : Use the immunity to organize the chemistry method to measure C - erbB - 2 gene at 32 cases of cervical carcinoma, the expressions of chronic 20 of palace neck inflammation ( contrast the group ). Whether examine ( Chi - Square Test ) and have a difference to examine C - erbB - 2 in the experiment group and contrast the expression in the group with the card side. Results : The positive expression rate in chronic palace neck inflammation , cervical carcinoma are organized of C - erbB - 2 is 68. 75% , 30% respectively, having a statistics meaning ( P 〈0. 05 ) between the two, the expression of C - erbB -2 and clinic of the cervical carcinoma present positive correlation ( P 〈0. 01 ) by stages. Conclusion: The factor that C -erbB -2 withers to die as influencing cells, C - erbB - 2 plays a certain role in the course of emergence , developing of the cervical carcinoma
出处 《中国优生与遗传杂志》 2009年第10期29-30,9,共3页 Chinese Journal of Birth Health & Heredity
基金 湖南省教育厅科学研究项目(编号:07C059)
关键词 宫颈癌 C—erbB-2 免疫组织化学 Carcinoma cervicis C - erbB - 2 Iimmunohistochemistry
  • 相关文献

参考文献9

  • 1Scheurle D, Jahanzeb M, Aronsohn RS, et al. HER -2/neu expression in archival non small cell lung carcinomas using FDA - approved Herceptin in test [ J ]. Anticancer Res ,2000,20 (3 B) :2091 - 2096.
  • 2Seliger B,Rongcun Y,Atkins D,et al. HER -2/neu is expressed in human renal cell carcinoma at heteror geneous levels independently of tumor grading and can be recognized by HLA -A2. 1 -restricted cytotoxic T lymphocytes [ J ]. Int J Cancer,2000,87 ( 3 ) :349 - 359.
  • 3Blume Jensen P, Hunter T. Oncogenic kinase singnaling[ J ]. Nature, 2001,411 ( 17 ) :355 - 365.
  • 4Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implication of the ErbB/HER signaling network of growth factor receptors [J]. Adv Canoe Res,2000,77( 1 ) :25 -30.
  • 5Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implication of the ErbB/HER signaling network of growth factor receptors [ J ]. Adv Cance Res,2000,77 ( 1 ) :25 - 30.
  • 6Slamon D J, Clark GM, Wong SG, et al . Human breast cancer: correlation of relapse and survival with amplificaeion of HER - 2/neuoncogene[ J]. Science, 1987,235 : 177.
  • 7刘晓燕,曲恒芳,伯凤京.C-erbB-2在子宫颈癌中的表达及临床意义[J].医学临床研究,2006,23(1):23-25. 被引量:2
  • 8Blume Jensen P, Hunter T. Oncongenic kinase signalling [ J ]. Nature,2001,411 (6835) :355 -356.
  • 9Mehlen P,et al. The DCCgene product induces apoptosis by a mechanism requiring receptor proteolysis[J]. Nature, 1998,395:801.

二级参考文献9

  • 1Scheurle D,Jahanzeb M,Aronsohn RS,et al.HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test[J].Anticancer Res,2000,20(3B):2091-2096.
  • 2Seliger B,Rongcun Y,Atkins D,et al.HER 2/neu is expressed in human renal cell carcinoma at hetero-geneous levels independently of tumor grading and can be recognized by HLA-Az.1-restricted cytotoxic T lymphocytes[J].Int J Cancer,2000,87(3):349-359.
  • 3Klapper LN,Kirschbaum MH,Sela M,et al.Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors[J].Adv Cancer Res,2000,77 (1):25-30.
  • 4Blume-Jensen P,Hunter T.Oncongenic kinase signalling[J].Nature,2001,411(6835):355-356.
  • 5Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplificaeion of HER-2/neuoncogene[J].Science,1987,235:177.
  • 6Hung MC,Hortobagyi GN,Ueno NT.Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer[J].Adv Erp Med Biol,2000,465:171-180.
  • 7Scott GK,Chang CH,Erny KM.Ets regulation of the erbB2 promoter[J].Oncogene,2000,19(55):6490-6502.
  • 8刘月仙,何传泰,焦士兰,李秀峰,王瑛,张春林.癌基因C-erbB_2在宫颈癌组织中表达的临床、病理及预后的意义[J].中国全科医学,1999,2(3):180-182. 被引量:3
  • 9姜天福,魏志敏,刘祖华,孟云霄,梁超群.子宫颈及子宫内膜肿瘤组织EGFR和c-erbB-2的表达及其意义[J].青岛大学医学院学报,2004,40(1):15-16. 被引量:3

共引文献1

同被引文献23

  • 1崔丽阳,赵树旺.宫颈癌免疫治疗与预防进展[J].医学综述,2006,12(13):796-798. 被引量:1
  • 2杨红玲,平宝红,王前,郑磊,唐雯,亓涛,包杰.IL-18单核苷酸多态性rs1946519和rs360718与宫颈癌的关系[J].南方医科大学学报,2007,27(7):1006-1008. 被引量:3
  • 3Lny,Zix,Plllak M.Molecular mechanism underlying IGF-1-inducedattention of the growth-inhibitory activity of trastuzumab(Herceptin)obskBR3 breast cancer cells[J].Int J Cancer,2004,108(3):334-341.
  • 4Brychtat E,Sedlakova E,Kolar Z,et al.Proto-oncogene C-myc in uterinecervix carcinoma genesis[J].Neoplasma,2004,51(2):84-90.
  • 5Sampedro CF,Cano SG,Sampedro SF,et al.Telomerase and telomeredynamics in ageing and cancer current status and future directions[J].Clin Transl Oncol,2007,9(3):145-154.
  • 6Wang SJ,Sakamoto T,Yasuda S,et al.The relationship between telomerelength and telomerase activety in gynecologic cancer[J].Gynecol Oncol,2002,84(1):81.
  • 7Castle PE.Byeond heman papillomavirus:the cervix,exogenous secondaryfactors,and the development of cervucal precancer and cancer[J].J LowGenit Tract Dis,2004,8(3):224-230.
  • 8Bais AG,Beckmann I,Lindemans J,et al.A shift to a peripheralTh2-type cytokine pattern during the carcinogenesis of cervical cancerbecomes manifest in CINⅢlesions[H].J Clin Pathol,2005,58(10):1096-1100.
  • 9Kuzuya K.Chemoradiotherapy for uterine cancer current status andperspectives[J].Int J Clin Oncol,2004,9(6):458-470.
  • 10Eifel PJ,Winter K,Morris M,et al.Pelvic irradiation with concurrentchemotherapy versus pelvic and para-aortic irradiation for high-riskcervical cancer:an update of the radiation therapy oncolofy group trial(RTOG)[J].The Women's Oncology Review,2004,4(2):119-120.

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部